



Major Article

Fluoxetine as a possible treatment for adult amblyopia: results of a double-blind, randomized, placebo-controlled trial

Arash Mirmohammadsadeghi MD^a, Alireza Mousavi MD^a, Mohammad Reza Akbari MD^a, Hassan Khojasteh MD^a, Babak Masoomian MD^a, Motahhareh Sadeghi MD^a, Samira Yadegari MD^a, Hassan Asadigandomani MD^{a b}

[Show more](#)

Share Cite

<https://doi.org/10.1016/j.jaapos.2024.104009>

[Get rights and content](#)

Abstract

Purpose

To evaluate the effects of oral fluoxetine on visual acuity and visual-evoked potential (VEP) parameters in adults with amblyopia.

Methods

In this randomized clinical trial, adults (>18 years of age) with anisometropic or strabismic amblyopia were assigned randomly to a treatment (fluoxetine) group or a placebo group. Standard treatments for amblyopia (glasses prescription and patching) were prescribed for 4 months for all patients. The first group received fluoxetine (20 mg per day) and the second group received a placebo for 3 months. Visual acuity evaluation and VEP were performed before and after treatment.

Results

A total of 55 participants were included: 29 in the fluoxetine group and 26 in the placebo group. Mean age was 27.2 ± 8.6 years (18-54). The mean logMAR visual acuity of the amblyopic eye improved by 0.20 ± 0.24 (0-0.8) in the fluoxetine group ($P < 0.001$) and by 0.08 ± 0.15 (0-0.7) in the placebo group ($P = 0.01$); mean logMAR improvement was significantly higher in the fluoxetine group than in the placebo group ($P = 0.04$). At the end of the study, mean visual acuity of the fluoxetine group (0.36 ± 0.21 log MAR) was better than the placebo group (0.43 ± 0.35 log MAR). Among the VEP parameters, N75 amplitude did not change significantly in either group relative to baseline, but the changes were statistically significantly different between the two groups ($P = 0.05$); N135 latency improved from baseline in the fluoxetine group ($P = 0.03$).

Conclusions

In our study cohort, fluoxetine treatment for adult amblyopia resulted in greater improvement in visual acuity than placebo.

Access through your organization

Check access to the full text by signing in through your organization.

Access through **your organization**

References (0)

Cited by (0)

[View full text](#)